Symbols / ENLV
ENLV Chart
About
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 249.25M |
| Enterprise Value | 9.71M | Income | -12.70M | Sales | — |
| Book/sh | 0.72 | Cash/sh | 0.75 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -3.28 | PEG | — |
| P/S | — | P/B | 1.46 | P/C | — |
| EV/EBITDA | -0.68 | EV/Sales | — | Quick Ratio | 6.26 |
| Current Ratio | 6.43 | Debt/Eq | 4.01 | LT Debt/Eq | — |
| EPS (ttm) | -0.54 | EPS next Y | -0.32 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 16:00 | ROA | -36.02% |
| ROE | -57.64% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 237.38M |
| Shs Float | 6.28M | Short Float | 0.22% | Short Ratio | 1.10 |
| Short Interest | — | 52W High | 2.10 | 52W Low | 0.66 |
| Beta | 1.59 | Avg Volume | 4.18M | Volume | 148.25K |
| Target Price | $13.00 | Recom | Buy | Prev Close | $1.12 |
| Price | $1.05 | Change | -6.25% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$13.00
Mean price target
2. Current target
$1.05
Latest analyst target
3. DCF / Fair value
$-0.42
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.05
Low
$13.00
High
$13.00
Mean
$13.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-12 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2025-11-24 | down | D. Boral Capital | Buy → Hold | — |
| 2025-10-29 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-09-26 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-09-12 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-09-02 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-08-22 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-08-18 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-07-29 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-07-22 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-04-21 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-04-03 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-03-24 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-03-03 | main | D. Boral Capital | Buy → Buy | $13 |
| 2025-02-07 | main | D. Boral Capital | Buy → Buy | $13 |
| 2024-12-11 | main | D. Boral Capital | Buy → Buy | $13 |
| 2024-12-03 | main | D. Boral Capital | Buy → Buy | $13 |
| 2024-11-14 | main | D. Boral Capital | Buy → Buy | $13 |
| 2024-09-27 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-09-26 | main | EF Hutton | Buy → Buy | $13 |
- Enlivex (Nasdaq: ENLV) raises $212M to launch RAIN prediction markets treasury plan - Stock Titan Mon, 24 Nov 2025 08
- EXCLUSIVE: Enlivex Raises Over $200 Million To Launch First Public Company Prediction Markets Play - Yahoo Finance Mon, 24 Nov 2025 08
- ENLV Stock Surges After Pivot To Crypto-Backed Treasury, Names Former Italian PM To Board - Stocktwits Mon, 24 Nov 2025 08
- Enlivex: A Necessary Update - This Is No Longer The Company We Covered In 2022 (NASDAQ:ENLV) - Seeking Alpha Sat, 13 Dec 2025 08
- ENLV: Analyst Raises Price Target Significantly | ENLV Stock New - GuruFocus Mon, 12 Jan 2026 12
- Short Interest in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Drops By 66.6% - MarketBeat Wed, 28 Jan 2026 08
- Enlivex Therapeutics Ltd. (ENLV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Fri, 13 Feb 2026 23
- Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation - simplywall.st ue, 07 Oct 2025 07
- New Analyst Forecast: $ENLV Given $13.0 Price Target - Nasdaq ue, 22 Jul 2025 07
- New Analyst Forecast: $ENLV Given $13 Price Target | ENLV Stock News - Quiver Quantitative Mon, 12 Jan 2026 08
- Enlivex stock gains on upbeat 6-month results in knee osteoarthritis trial - MSN Mon, 24 Nov 2025 17
- Why ENLV stock is a must watch in 2025 - Weekly Earnings Recap & Technical Confirmation Trade Alerts - mfd.ru Sat, 14 Feb 2026 16
- RAIN token jumps to Kraken, second-largest US crypto exchange - Stock Titan ue, 10 Feb 2026 08
- Enlivex Lists RAIN Treasury Token on WhiteBIT to Boost Liquidity - The Globe and Mail ue, 27 Jan 2026 08
- Enlivex stock soars after positive knee osteoarthritis trial data - Investing.com Mon, 18 Aug 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -13.25M | -18.85M | -18.94M | -23.77M |
| TotalUnusualItems | -1.14M | -5.47M | -6.08M | 5.03M |
| TotalUnusualItemsExcludingGoodwill | -1.14M | -5.47M | -6.08M | 5.03M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -15.01M | -29.07M | -31.06M | -14.47M |
| ReconciledDepreciation | 545.00K | 835.00K | 777.00K | 546.00K |
| EBITDA | -14.39M | -24.32M | -25.02M | -18.74M |
| EBIT | -14.93M | -25.15M | -25.80M | -19.29M |
| NetInterestIncome | 1.06M | 1.55M | 821.00K | -208.00K |
| InterestIncome | 1.07M | 1.56M | 835.00K | 120.00K |
| NormalizedIncome | -13.88M | -23.60M | -24.98M | -19.50M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -15.01M | -29.07M | -31.06M | -14.47M |
| TotalExpenses | 14.93M | 25.15M | 25.80M | 19.29M |
| TotalOperatingIncomeAsReported | -15.89M | -29.39M | -25.80M | -19.29M |
| DilutedAverageShares | 20.51M | 18.57M | 18.39M | 17.86M |
| BasicAverageShares | 20.51M | 18.57M | 18.39M | 17.86M |
| DilutedEPS | -0.73 | -1.56 | -1.69 | -0.81 |
| BasicEPS | -0.73 | -1.56 | -1.69 | -0.81 |
| DilutedNIAvailtoComStockholders | -15.01M | -29.07M | -31.06M | -14.47M |
| NetIncomeCommonStockholders | -15.01M | -29.07M | -31.06M | -14.47M |
| NetIncome | -15.01M | -29.07M | -31.06M | -14.47M |
| NetIncomeIncludingNoncontrollingInterests | -15.01M | -29.07M | -31.06M | -14.47M |
| NetIncomeContinuousOperations | -15.01M | -29.07M | -31.06M | -14.47M |
| PretaxIncome | -15.01M | -29.07M | -31.06M | -14.47M |
| OtherIncomeExpense | -1.14M | -5.47M | -6.08M | 5.03M |
| SpecialIncomeCharges | -957.00K | -4.24M | 0.00 | 0.00 |
| GainOnSaleOfPPE | -957.00K | -4.24M | 0.00 | 0.00 |
| GainOnSaleOfSecurity | -182.00K | -1.22M | -6.08M | 5.03M |
| NetNonOperatingInterestIncomeExpense | 1.06M | 1.55M | 821.00K | -208.00K |
| TotalOtherFinanceCost | 13.00K | 14.00K | 14.00K | 328.00K |
| InterestIncomeNonOperating | 1.07M | 1.56M | 835.00K | 120.00K |
| OperatingIncome | -14.93M | -25.15M | -25.80M | -19.29M |
| OperatingExpense | 14.93M | 25.15M | 25.80M | 19.29M |
| OtherOperatingExpenses | 105.00K | 906.00K | 402.00K | 167.00K |
| OtherTaxes | -605.00K | 0.00 | 0.00 | |
| ResearchAndDevelopment | 10.62M | 19.01M | 18.69M | 12.88M |
| SellingGeneralAndAdministration | 4.81M | 5.23M | 6.70M | 6.24M |
| GeneralAndAdministrativeExpense | 4.81M | 5.23M | 6.70M | 6.24M |
| OtherGandA | 1.26M | 1.44M | 2.00M | 1.45M |
| InsuranceAndClaims | 351.00K | 567.00K | 895.00K | 783.00K |
| SalariesAndWages | 3.20M | 3.23M | 3.81M | 4.01M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 23.65M | 18.60M | 18.42M | 18.33M |
| ShareIssued | 23.65M | 18.60M | 18.42M | 18.33M |
| TotalDebt | 534.00K | 1.03M | 4.85M | 6.01M |
| TangibleBookValue | 23.59M | 30.08M | 56.84M | 85.04M |
| InvestedCapital | 23.59M | 30.08M | 56.84M | 85.04M |
| WorkingCapital | 22.19M | 27.70M | 45.72M | 81.72M |
| NetTangibleAssets | 23.59M | 30.08M | 56.84M | 85.04M |
| CapitalLeaseObligations | 534.00K | 1.03M | 4.85M | 6.01M |
| CommonStockEquity | 23.59M | 30.08M | 56.84M | 85.04M |
| TotalCapitalization | 23.59M | 30.08M | 56.84M | 85.04M |
| TotalEquityGrossMinorityInterest | 23.59M | 30.08M | 56.84M | 85.04M |
| StockholdersEquity | 23.59M | 30.08M | 56.84M | 85.04M |
| GainsLossesNotAffectingRetainedEarnings | 1.10M | 1.10M | 1.10M | 1.10M |
| OtherEquityAdjustments | 1.10M | 1.10M | ||
| ForeignCurrencyTranslationAdjustments | 1.10M | 1.10M | 1.10M | |
| RetainedEarnings | -127.11M | -112.09M | -83.03M | -51.97M |
| AdditionalPaidInCapital | 146.91M | 138.94M | 136.65M | 133.80M |
| CapitalStock | 2.69M | 2.14M | 2.12M | 2.11M |
| CommonStock | 2.69M | 2.14M | 2.12M | 2.11M |
| TotalLiabilitiesNetMinorityInterest | 4.10M | 6.75M | 10.80M | 10.11M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 299.00K | 686.00K | 4.19M | 5.39M |
| OtherNonCurrentLiabilities | 5.39M | |||
| LongTermDebtAndCapitalLeaseObligation | 299.00K | 686.00K | 4.19M | 5.39M |
| LongTermCapitalLeaseObligation | 299.00K | 686.00K | 4.19M | 5.39M |
| CurrentLiabilities | 3.80M | 6.06M | 6.61M | 4.72M |
| OtherCurrentLiabilities | 142.00K | 1.23M | ||
| CurrentDebtAndCapitalLeaseObligation | 235.00K | 346.00K | 653.00K | 617.00K |
| CurrentCapitalLeaseObligation | 235.00K | 346.00K | 653.00K | 617.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.41M | 889.00K | 759.00K | 1.07M |
| PayablesAndAccruedExpenses | 2.02M | 3.59M | 5.20M | 3.03M |
| CurrentAccruedExpenses | 1.20M | 2.77M | 3.25M | 2.15M |
| Payables | 811.00K | 827.00K | 1.95M | 878.00K |
| DuetoRelatedPartiesCurrent | 113.00K | |||
| AccountsPayable | 811.00K | 827.00K | 1.95M | 878.00K |
| TotalAssets | 27.69M | 36.83M | 67.64M | 95.15M |
| TotalNonCurrentAssets | 1.69M | 3.07M | 15.31M | 8.70M |
| OtherNonCurrentAssets | 317.00K | 300.00K | 299.00K | 321.00K |
| NonCurrentPrepaidAssets | 18.00K | 187.00K | 113.00K | 164.00K |
| NonCurrentAccountsReceivable | 206.00K | |||
| InvestmentsAndAdvances | 3.00K | |||
| OtherInvestments | 3.00K | |||
| NetPPE | 1.15M | 2.58M | 14.90M | 8.22M |
| AccumulatedDepreciation | -3.65M | -3.99M | -3.53M | -1.97M |
| GrossPPE | 4.80M | 6.57M | 18.43M | 10.19M |
| Leases | 947.00K | 1.43M | 8.61M | 1.52M |
| OtherProperties | 3.27M | 4.55M | 9.30M | 8.22M |
| MachineryFurnitureEquipment | 586.00K | 591.00K | 525.00K | 448.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 25.99M | 33.76M | 52.33M | 86.44M |
| AssetsHeldForSaleCurrent | 198.00K | 5.11M | 0.00 | |
| RestrictedCash | 113.00K | 113.00K | ||
| PrepaidAssets | 884.00K | 1.11M | 1.44M | 1.11M |
| Receivables | 1.42M | 229.00K | 647.00K | 1.09M |
| OtherReceivables | 1.35M | 113.00K | 125.00K | 14.00K |
| TaxesReceivable | 68.00K | 116.00K | 522.00K | 1.07M |
| AccountsReceivable | 2.20M | |||
| CashCashEquivalentsAndShortTermInvestments | 23.50M | 27.32M | 50.24M | 84.13M |
| OtherShortTermInvestments | 20.20M | 26.51M | 299.00K | 72.93M |
| CashAndCashEquivalents | 3.30M | 813.00K | 49.95M | 11.20M |
| CashEquivalents | 1.04M | 0.00 | 47.82M | 10.00M |
| CashFinancial | 2.26M | 813.00K | 2.12M | 1.20M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -13.11M | -23.76M | -32.08M | -19.17M |
| IssuanceOfCapitalStock | 6.45M | 360.00K | 0.00 | 53.17M |
| CapitalExpenditure | -103.00K | -236.00K | -8.12M | -1.62M |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 3.73M | 1.23M | 50.36M | 11.64M |
| BeginningCashPosition | 1.23M | 50.36M | 11.64M | 7.01M |
| EffectOfExchangeRateChanges | 0.00 | 0.00 | -408.00K | |
| ChangesInCash | 2.50M | -49.13M | 38.72M | 5.03M |
| FinancingCashFlow | 6.45M | 360.00K | 150.00K | 60.98M |
| CashFlowFromContinuingFinancingActivities | 6.45M | 360.00K | 150.00K | 60.98M |
| ProceedsFromStockOptionExercised | 2.00K | 0.00 | 150.00K | 7.81M |
| NetCommonStockIssuance | 6.45M | 360.00K | 0.00 | 53.17M |
| CommonStockIssuance | 6.45M | 360.00K | 0.00 | 53.17M |
| InvestingCashFlow | 9.06M | -25.97M | 62.52M | -38.41M |
| CashFlowFromContinuingInvestingActivities | 9.06M | -25.97M | 62.52M | -38.41M |
| NetInvestmentPurchaseAndSale | 8.98M | -25.86M | 70.65M | -36.78M |
| SaleOfInvestment | 41.35M | 301.00K | 72.55M | 67.63M |
| PurchaseOfInvestment | -32.37M | -26.17M | -1.91M | -104.42M |
| NetPPEPurchaseAndSale | 81.00K | -103.00K | -8.12M | -1.62M |
| SaleOfPPE | 184.00K | 133.00K | 0.00 | 0.00 |
| PurchaseOfPPE | -103.00K | -236.00K | -8.12M | -1.62M |
| OperatingCashFlow | -13.01M | -23.52M | -23.95M | -17.54M |
| CashFlowFromContinuingOperatingActivities | -13.01M | -23.52M | -23.95M | -17.54M |
| ChangeInWorkingCapital | -1.22M | -1.82M | 804.00K | -1.36M |
| ChangeInOtherCurrentLiabilities | -591.00K | -955.00K | -1.33M | -84.00K |
| ChangeInPayablesAndAccruedExpense | -1.06M | -1.47M | 1.85M | -24.00K |
| ChangeInAccruedExpense | -1.04M | -350.00K | 684.00K | -466.00K |
| ChangeInPayable | -16.00K | -1.12M | 1.17M | 442.00K |
| ChangeInAccountPayable | -16.00K | -1.12M | 1.17M | 442.00K |
| ChangeInPrepaidAssets | 433.00K | 608.00K | 278.00K | -1.25M |
| OtherNonCashItems | 297.00K | 696.00K | 831.00K | 413.00K |
| StockBasedCompensation | 2.06M | 1.95M | 2.71M | 2.91M |
| DepreciationAmortizationDepletion | 545.00K | 835.00K | 777.00K | 546.00K |
| DepreciationAndAmortization | 545.00K | 835.00K | 777.00K | 546.00K |
| Depreciation | 545.00K | 835.00K | 777.00K | 546.00K |
| OperatingGainsLosses | 317.00K | 3.88M | 1.98M | -5.59M |
| PensionAndEmployeeBenefitExpense | 0.00 | |||
| GainLossOnInvestmentSecurities | -558.00K | -343.00K | 1.98M | -5.59M |
| GainLossOnSaleOfPPE | -82.00K | -20.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -15.01M | -29.07M | -31.06M | -14.47M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for ENLV
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|